MSLN and neoplasm: While MSLN inhibition is expected to induce a senescent phenotype in PDAC cells via the activation of the P53/P21 and P16/RB pathways, senolytics could be used to selectively clear these senescent tumor cells, potentially reducing the pro-tumorigenic effects of chronic SASP secretion (e.g., IL-6 and IL-8).